Kimberly-Clark (NYSE: KMB) just announced a $48.7 billion cash-and-stock deal to acquire Kenvue (NYSE: KVUE) — the company behind Tylenol, Band-Aid, and Neutrogena. Before the market opened, Kenvue stock surged 20.95% to $17.38, while Kimberly-Clark fell 14%. The deal values Kenvue at roughly $21 per share (about $40.3 billion in equity) and is expected to close in the second half of 2026. The combined company would generate $32 billion in annual revenue and projects $1.9 billion in cost synergies within three years of completion. Kenvue, spun off from Johnson & Johnson in 2023, had seen its shares slide 35% from IPO levels before this merger was announced. #KimberlyClark #Kenvue #Tylenol #Kleenex #BandAid #JohnsonAndJohnson 🖥️ Try Benzinga Pro FREE with a 14 day trial: benzinga.com/pro/register 📈 Take your trading to the next level with our suite of premium research services and tools: benzinga.com/services 🌐 Find more market-moving insights at https:/...